Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

This study has been completed.
Information provided by (Responsible Party):
Seattle Genetics, Inc. Identifier:
First received: January 25, 2006
Last updated: December 17, 2014
Last verified: December 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2010
  Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)